Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — WFH 2026 World Congress
5 slides from Inovio Pharmaceuticals's conference presentation, Apr 22, 2026
Slide 1: FVIII expression via non-viral vector
FVIII expression via non-viral vector DNA medicine platform results in efficacious levels of FVIII protein and correction of the bleeding phenotype in hemophilia A mice Michael Sumner, MD Chief Medical Officer and Head of Development, Inovio April 22, 2026 WFH 2026 World Congress
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding o
Slide 3: DNA Medicine Technology Platform
DNA Medicine Technology Platform • Synthetic plasmid DNA constructs are administered intramuscularly (IM) followed by in vivo electroporation (EP) for the local expression of the transgenes in the deltoid muscle • DNA-encoded proteins (DPROTs) are expressed in the myocytes and secreted into circulat
Slide 4: Bleeding Phenotype Correction in Hemophilia A Mice Following in vivo FVIII Gene Transfer
Bleeding Phenotype Correction in Hemophilia A Mice Following in vivo FVIII Gene Transfer by EP in Skeletal Muscle Cells Functional FVIII activity measurements by Activated Efficacy assessment by tail bleeding model Partial Thromboplastin Time (APTT) clotting assay A B C ns ✱ 0.8 ✱ 40.0 300 ns ✱ ns (
Slide 5: Conclusions
Conclusions • Preclinical proof-of-concept for a novel human FVIII replacement therapeutic modality, demonstrating in vivo production of functional FVIII and correction of the bleeding phenotype in FVIII KO HA mice • Plasma from INO-D001-treated HA mice showed clotting activity comparable to WT mice